Neutrogena is facing public backlash over a campaign featuring actress Hayden Panettiere, and the controversy has weighed on the stock price of its parent company, according to BusinessGhana.
The report, published Wednesday, Aug. 26, 2026, says the negative reaction to the ad campaign has hurt investor sentiment. BusinessGhana did not provide details on the specific content of the advertisement or the exact size of the stock decline.
The backlash has also drawn criticism from public relations professionals. Business Insider reported that experts called Neutrogena’s response to the controversy “botched,” while PR Week UK quoted industry figures expressing sympathy for the brand’s communications team. Yahoo published a copy of Neutrogena’s official statement on the matter, though the substance of that statement was not included in the available summary.
Separately, Baptist News Global connected the Panettiere backlash to broader discussions about support for mothers, referencing Lindsay Clancy, a Massachusetts woman accused of killing her three children in 2023. That outlet’s piece suggests the controversy has touched on wider societal questions about maternal mental health, though the exact link to the Neutrogena campaign was not spelled out in the summary.
The situation highlights how quickly a celebrity endorsement can turn into a corporate liability, especially when the public response is seen as inadequate. For Neutrogena, the immediate challenge is stabilizing its parent company’s stock while managing a narrative that PR experts say has already gone off track.
What to watch next: whether Neutrogena issues a revised statement or takes further action to address the criticism, and how long the stock pressure lasts.
